RecruitingPhase 1NCT07262983
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Studying Autosomal dominant hyper-IgE syndrome due to STAT3 deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Alexandra F Freeman, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- baricitinib(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 12-120 years · All sexes
- Timeline
- 2026 – 2030
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07262983 on ClinicalTrials.gov